Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NCOA2
REST API REST API
Homo sapiens
NCOA2 is differentially expressed in 324 experiments: 117 organism parts: liver, heart, ... (115 more);, 217 disease states: normal, glioblastoma, ... (215 more);, 95 cell types 462 cell lines 51 compound treatments and 82 other conditions.
Synonyms GRIP1, NCoA-2, KAT13C, bHLHe75, TIF2
Orthologs NCOA2 (Gallus gallus)   ncoa2 (Danio rerio)   Ncoa2 (Mus musculus)   NCOA2 (Bos taurus)   Ncoa2 (Rattus norvegicus)   ncoa2 (Xenopus laevis)   NCOA2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term rough endoplasmic reticulum, DNA binding, ligand-dependent nuclear receptor binding, negative regulation of transcription, DNA-dependent, protein binding, histone acetyltransferase activity, regulation of transcription, DNA-dependent, cytoplasm, Golgi apparatus, receptor binding, signal transducer activity, positive regulation of transcription from RNA polymerase II promoter, microtubule, transcription coactivator activity, nucleus, postsynaptic density, dendrite, ligand-dependent nuclear receptor transcription coactivator activity, chromatin binding, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, PDZ domain binding, presynaptic active zone, signal transduction, neuronal cell body, androgen receptor signaling pathway, cerebellum development, nuclear hormone receptor binding, thyroid hormone receptor coactivator activity, cellular lipid metabolic process
InterPro Term PAS, PAS_fold, Nuc_rcpt_coact_Ncoa-typ, Nuclear_rcpt_coactivator, DUF1518, SRC-1, HLH_DNA-bd
UniProt Accession Q15596, E7EWM1, F8WAJ2
Search EB-eye ENSG00000140396
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-TABM-420, E-GEOD-14990
NCI-H929
2
E-MEXP-1269, E-MTAB-62
SW480
1
2
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
456 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-21909, E-GEOD-21750, ... (49 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-AFMX-5, E-TABM-145
fibroblast
1
2
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
germ cell
1
E-MTAB-25
monolayer recovery
1
E-GEOD-4219
BDCA3+ dendritic cell
1
1
E-TABM-34
B-cell
1
1
E-GEOD-10820
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (65 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
glioblastoma
1
3
E-GEOD-4290, E-GEOD-4412, E-MTAB-37, E-GEOD-6014
septic shock
2
E-GEOD-8121, E-GEOD-9692
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
embryonal rhabdomyosarcoma
2
E-MEXP-121, E-MTAB-62
211 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
2
E-MEXP-1958, E-TABM-868, E-GEOD-3720
MIG control
1
E-GEOD-15811
hydrogen peroxide
1
E-GEOD-5339
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
unknown
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
45 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
88 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-1956, E-MEXP-2069, ... (44 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.502 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM